Influence of Age at Diagnosis and Time-Dependent Risk Factors on the Development of Diabetic Retinopathy in Patients with Type 1 Diabetes.

J Diabetes Res

Department of Endocrinology and Nutrition, Complejo Hospitalario de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Calle Irunlarrea 3, Pamplona, 31008 Navarra, Spain.

Published: May 2017


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Aim. To determine the influence of age at onset of type 1 diabetes and of traditional vascular risk factors on the development of diabetic retinopathy, in a cohort of patients who have been followed up after onset. Methods. Observational, retrospective study. The cohort consists of 989 patients who were followed up after diagnosis for a mean of 10.1 (SD: 6.8) years. The influence of age at diagnosis, glycemic control, duration of diabetes, sex, blood pressure, lipids, BMI, and smoking is analyzed using Cox univariate and multivariate models with fixed and time-dependent variables. Results. 135 patients (13.7%) developed diabetic retinopathy. The cumulative incidence was 0.7, 5.9, and 21.8% at 5-, 10-, and 15-year follow-up, respectively. Compared to the group with onset at age <10 years, the risk of retinopathy increased 2.5-, 3-, 3.3-, and 3.7-fold in the groups with onset at 10-14, 15-29, 30-44, and >44 years, respectively. During follow-up we also observed an association between diabetic retinopathy and HbA1c levels, HDL-cholesterol, and diastolic blood pressure. Conclusion. The rate of diabetic retinopathy is higher in patients who were older at type 1 diabetes diagnosis. In addition, we confirmed the influence of glycemic control, HDL-cholesterol, and diastolic blood pressure on the occurrence of retinopathy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861784PMC
http://dx.doi.org/10.1155/2016/9898309DOI Listing

Publication Analysis

Top Keywords

diabetic retinopathy
20
influence age
12
type diabetes
12
blood pressure
12
age diagnosis
8
risk factors
8
factors development
8
development diabetic
8
glycemic control
8
hdl-cholesterol diastolic
8

Similar Publications

Diabetic retinopathy (DR) remains a leading cause of preventable blindness worldwide, with the affected population projected to reach 270 million by 2045. Our study analyzed 2 434 interventional trials registered between 2007 and 2024 in the Informa Pharma Intelligence database and found that anti-VEGF agents dominate the therapeutic landscape-bevacizumab represents 24.0 % of studies, ranibizumab 15.

View Article and Find Full Text PDF

Purpose: To evaluate macular vessel density using clinical parameters in patients with type 2 diabetes mellitus (DM) without retinopathy.

Patients And Methods: This cross-sectional study enrolled 32 participants (63 eyes) aged 40-60 years who met the inclusion criteria. Group 1 included 32 eyes of type 2 DM, whereas the rest had no DM.

View Article and Find Full Text PDF

Organoids: their emerging essential role in pathological mechanisms and drug discovery of diabetes and its complications.

Front Pharmacol

August 2025

State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing, China.

Diabetes mellitus is a metabolic disease with a high global prevalence, which affects blood vessels throughout the entire body. As the disease progresses, it often leads to complications, including diabetic retinopathy and nephropathy. Currently, in addition to traditional cellular and animal models, more and more organoid models have been used in the study of diabetes and have broad application prospects in the field of pharmacological research.

View Article and Find Full Text PDF

Background: Artificial intelligence (AI) algorithms offer an effective solution to alleviate the burden of diabetic retinopathy (DR) screening in public health settings. However, there are challenges in translating diagnostic performance and its application when deployed in real-world conditions.

Objective: This study aimed to assess the technical feasibility of integration and diagnostic performance of validated DR screening (DRS) AI algorithms in real-world outpatient public health settings.

View Article and Find Full Text PDF

Dapagliflozin improves diabetic retinopathy in mice by inhibiting LAMA1 and regulating the PI3K/AKT signaling pathway.

Biochem Biophys Res Commun

September 2025

Department of Ophthalmology, Hebei Medical University, NO. 361 Zhongshan East Road, Changan District, Shijiazhuang City, Hebei Province, China; Department of Ophthalmology, Hebei General Hospital, NO. 348 Heping West Road, Xinhua District, Shijiazhuang City, Hebei Province, China. Electronic address

Diabetic retinopathy (DR) is among the most prevalent complications linked to advanced diabetes. Capillary Basement membrane (CBM) thickening is an early clinical manifestation in DR, and Laminin α 1 (LAMA1) is one of the main extracellular matrix components involved in CBM formation. Dapagliflozin (DAPA) has demonstrated efficacy in ameliorating DR.

View Article and Find Full Text PDF